Journal Article
. 2013 Oct; 96(6):1943-51.
doi: 10.1016/j.athoracsur.2013.07.089.

Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection

Bing-Sheng Sun 1 Yue Li  Zhen-Fa Zhang  Jian You  Chang-Li Wang  
  • PMID: 24094519
  •     20 citations


Background: Osteopontin (OPN) is identified as one of the leading genes that promote the metastasis of malignant tumor through binding to CD44v6 and integrin. The purpose of the current study was to assess the prognostic significance of OPN and CD44v6 in patients with non-small cell lung cancer (NSCLC).

Methods: Tissue microarray was used to detect the expression of OPN and CD44v6 in 159 NSCLC patients undergoing complete pulmonary resection in our hospital between 2003 and 2006. The correlations among OPN, CD44v6, and clinicopathologic data were analyzed using χ(2) testing analysis. The prognostic values of OPN and CD44v6 were evaluated by univariate Kaplan-Meier survival analysis and multivariate Cox proportional hazard model analysis.

Results: OPN and CD44v6 were both independent predictors for overall survival and disease-free survival. When OPN and CD44v6 were considered together, the predictive range was extended and the sensitivity was improved, especially for those patients with stage I NSCLC. The 6-year overall survival and disease-free survival rates in OPN+ or CD44v6+ patients were 49.1% and 39.6%, respectively, which were significantly lower than those of OPN-/CD44v6- patients (64.4% and 47.7%, respectively), and were higher than those of OPN+/CD44v6+ patients (16.4% and 14.8%, respectively). Stratification into OPN+/CD44v6+, OPN+ or CD44v6+, or OPN-/CD44v6- groups, based on the expression OPN and CD44v6, could efficiently predicted outcomes (p < 0.001) of NSCLC patients.

Conclusions: The combination of OPN and CD44v6 is a valuable independent predictor of tumor recurrence and survival in NSCLC patients.

Keywords: 10.

CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
Zhonghu Li, Kai Chen, +3 authors, Zhihua Li.
Diagn Pathol, 2014 Apr 09; 9. PMID: 24708709    Free PMC article.
The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.
Tao Zhang, Dong-Ming Zhang, +4 authors, Shou-Cheng Ma.
J Mol Histol, 2014 May 13; 45(5). PMID: 24816798
Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.
Hao Jiang, Wei Zhao, Wei Shao.
Tumour Biol, 2014 Jun 11; 35(8). PMID: 24913707
Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Ci Hui Yan, Mengguo Lv, +4 authors, Xiubao Ren.
J Cancer Res Clin Oncol, 2015 Jan 04; 141(8). PMID: 25555465
Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis.
Bin Peng, Yi-Han Wang, +2 authors, Yong-Sheng Wang.
Int J Clin Exp Med, 2015 Feb 11; 7(12). PMID: 25663958    Free PMC article.
Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5.
Álvaro Ruibal, Pablo Aguiar, +3 authors, Michel Herranz.
Int J Mol Sci, 2015 Mar 27; 16(3). PMID: 25809603    Free PMC article.
Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.
Yang Liu, Xiaobin Gu, +5 authors, Kexing Fan.
Int J Clin Exp Med, 2015 Nov 10; 8(8). PMID: 26550190    Free PMC article.
[Advances in Research of Osteopontion and Its Receptor CD44v in Tumor Invasion and Metastasis].
Bingsheng Sun, Zhenfa Zhang.
Zhongguo Fei Ai Za Zhi, 2015 Nov 20; 18(11). PMID: 26582229    Free PMC article.
The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.
Ying Wang, Jin Yang, +5 authors, You-Jin Lu.
Onco Targets Ther, 2015 Dec 10; 8. PMID: 26648743    Free PMC article.
Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer.
Ying Sun, Dan Li, +4 authors, Xian-Dong Li.
J Res Med Sci, 2016 Mar 10; 20(12). PMID: 26958047    Free PMC article.
Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis.
Dan Li, Wang Qian, +3 authors, Yanmin Wu.
Biomed Rep, 2016 Apr 29; 4(5). PMID: 27123248    Free PMC article.
Human osteopontin: Potential clinical applications in cancer (Review).
Chengcheng Hao, Yuxin Cui, +3 authors, Wen G Jiang.
Int J Mol Med, 2017 Apr 26; 39(6). PMID: 28440483    Free PMC article.
Osteopontin -- a promising biomarker for cancer therapy.
Ran Wei, Janet Pik Ching Wong, Hang Fai Kwok.
J Cancer, 2017 Aug 19; 8(12). PMID: 28819419    Free PMC article.
The biology and role of CD44 in cancer progression: therapeutic implications.
Chen Chen, Shujie Zhao, Anand Karnad, James W Freeman.
J Hematol Oncol, 2018 May 12; 11(1). PMID: 29747682    Free PMC article.
Highly Cited. Review.
Osteopontin expression is associated with progression and adverse prognosis in patients with resectable gastrointestinal stromal tumor.
Jinhai Wang, Xiaobin Cheng, Sen Lu, Weina Fan.
Int J Clin Exp Pathol, 2020 Jan 15; 12(4). PMID: 31933953    Free PMC article.
Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.
Anne-Sophie Lamort, Ioanna Giopanou, Ioannis Psallidas, Georgios T Stathopoulos.
Cells, 2019 Aug 07; 8(8). PMID: 31382483    Free PMC article.
Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients.
Lui Ng, Virginia Kwan, +4 authors, Wai-Lun Law.
BMC Cancer, 2019 Jul 22; 19(1). PMID: 31324164    Free PMC article.
CD44 as a tumor biomarker and therapeutic target.
Hanxiao Xu, Mengke Niu, +2 authors, Aiguo Liu.
Exp Hematol Oncol, 2020 Dec 12; 9(1). PMID: 33303029    Free PMC article.
Osteopontin Signaling in Shaping Tumor Microenvironment Conducive to Malignant Progression.
Ramesh Butti, Totakura V S Kumar, +3 authors, Gopal C Kundu.
Adv Exp Med Biol, 2021 Oct 20; 1329. PMID: 34664250
Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Yue Li, Hailin Liu, +5 authors, Changli Wang.
Thorac Cancer, 2021 Aug 24; 12(20). PMID: 34423566    Free PMC article.